Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

Anyone following the rhetoric around <keyword id="107950" type="General" weightage="100" keywordseo="Artificial-Intelligence" source="Orion">artificial intelligence</keyword> in recent years has heard one version or another of the cl<keyword id="6355999" type="General" weightage="20" keywordseo="AI" source="Orion">ai</keyword>m that AI is inevitable. Common themes are that AI is already here and indispensable, and people who are bearish on it harm themselves. In the business world, AI advocates tell companies and workers that they will fall behind if they fail to integrate generative AI into their operations. In the sciences, AI advocates promise that AI will aid in curing hitherto intractable diseases. In higher education, AI promoters admonish teachers that students must learn how to use AI or risk becoming uncompetitive when it comes time to find a job. In national security, AI's champions say that either the nation invests heavily in AI weaponry, or it will be at a disadvantage against the Chinese and Russians, who are already doing so. The argument across these different domains is essentially the same: The time for AI skepticism has come and gone. The <keyword id="6355118" type="General" weightage="20" keywordseo="technology" source="Orion">technology</keyword> will shape the future, whether you like it or not. You have the choice to learn how to use it or be left out of that future. Anyone trying to stand in the technology's way is as hopeless as the manual weavers who resisted the mechanical looms in the early 19th century. In the past few years, my colleagues and I (Nir Eisikovits, Professor of Philosophy and Director, Applied Ethics Center, UMass Boston) have been studying the ethical questions raised by the widespread adoption of AI, and I believe the inevitability argument is misleading. <h2>History and hindsight</h2> This claim is the most recent version of a deterministic view of technological development. It's the belief that innovations are unstoppable once people start working on them. In other words, some genies don't go back in their bottles. The best you can do is harness them for your good purposes. This deterministic approach to tech has a long history. It's been applied to the influence of the printing press as well as to the rise of automobiles and the infrastructure they require, among other developments. But I believe that when it comes to AI, the technological determinism argument is both exaggerated and oversimplified. <h2>AI in the field(s)</h2> Consider the contention that businesses can't afford to stay out of the AI game. The case has yet to be made that AI is delivering significant productivity gains to the firms that use it. A report in The <keyword id="20856675" type="General" weightage="20" keywordseo="economist" source="keywords">Economist</keyword> in July 2024 suggests that so far, the technology has had almost no economic impact. AI's role in higher education is also still very much an open question. Though universities have, in the past two years, invested heavily in AI-related initiatives, evidence suggests they may have jumped the gun. The technology can serve as an interesting pedagogical tool. For example, creating a Plato chatbot that lets students have a text conversation with a bot posing as Plato is a cool gimmick. However, AI is already starting to displace some of the best tools teachers have for assessment and for developing critical thinking, such as writing assignments. The college essay is going the way of the dinosaurs as more teachers give up on the ability to tell whether their students are writing their papers themselves. What's the cost-benefit argument for giving up on writing, an important and useful traditional skill? In the sciences and medicine, the use of AI seems promising. Its role in understanding the structure of proteins, for example, will likely be significant for curing diseases. The technology is also transforming medical imaging and has been helpful in accelerating the drug discovery process. But the excitement can become exaggerated. AI-based predictions about which cases of COVID-19 would become severe have roundly failed, and doctors rely excessively on the technology's diagnostic ability, often against their own better clinical judgment. And so, even in this area, where the potential is great, AI's ultimate impact is unclear. In national security, the argument for investing in AI development is compelling. Since the stakes can be high, the argument that if the Chinese and the Russians are developing AI-driven autonomous weapons, the United States can't afford to fall behind has real purchase. But a complete surrender to this form of reasoning, though tempting, is likely to lead the <keyword id="19899807" type="General" weightage="20" keywordseo="u-s-" source="keywords">U.S.</keyword> to overlook the disproportionate impact of these systems on nations that are too poor to participate in the AI arms race. The major powers could deploy the technology in conflicts in these nations. And, just as significantly, this argument de-emphasizes the possibility of collaborating with adversaries on limiting military AI systems, favoring arms race over arms control.<h2> One step at a time</h2> Surveying the potential significance and risks of AI in these different domains merits some skepticism about the technology. I believe that AI should be adopted piecemeal and with a nuanced approach rather than subject to sweeping claims of inevitability. In developing this careful take, there are two things to keep in mind: -First, companies and entrepreneurs working on artificial intelligence have an obvious interest in the technology being perceived as inevitable and necessary, since they make a living from its adoption. It's important to pay attention to who is making claims of inevitability, and why. -Second, it's worth taking a lesson from recent history. Over the past 15 years, smartphones and the social media apps that run on them have come to be seen as a fact of life - a technology as transformative as it is inevitable. Then data started emerging about the <keyword id="6354774" type="General" weightage="20" keywordseo="mental-health" source="Orion">mental health</keyword> harms they cause teens, especially young girls. School districts across the United States started to ban phones to protect the attention spans and mental health of their students. And some people have reverted to using flip phones as a quality of life change to avoid smartphones. After a long experiment with the mental health of kids, facilitated by claims of technological determinism, Americans changed course. What seemed fixed turned out to be alterable. There is still time to avoid repeating the same mistake with artificial intelligence, which potentially could have larger consequences for society.

Is AI dominance inevitable? A technology ethicist says no, actually

As many as 290 cases of <keyword id="21545939" type="General" weightage="20" keywordseo="KP-2" source="keywords">KP.2</keyword> and 34 cases of <keyword id="21748081" type="General" weightage="20" keywordseo="KP-1" source="keywords">KP.1</keyword>, both sub-lineages of COVID-19 that are responsible for surge in cases in Singapore, have been found in India, according to official data. However, a source in the Union health ministry told PTI that they are all sub variants of <keyword id="20115417" type="General" weightage="20" keywordseo="JN1" source="keywords">JN1</keyword> and there is no associated increase in hospitalisation and severe cases. "So there is no reason for concern or panic. The mutations will keep happening at a rapid pace and this is the natural behaviour of viruses like SARS-CoV2," the source said. The source further said that the INSACOG surveillance is sensitive and is able to pick up the emergence of any new variant and samples are also picked from hospitals in a structured manner to detect any change in the severity of disease due to virus. Data compiled by the Indian SARS-CoV-2 Genomics Consortium (INSACOG) showed that 34 cases of KP.1 have been found across seven states and UTs with 23 cases registered from West Bengal. The other states are Goa (1), Gujarat (2), Haryana (1), Maharashtra (4) Rajasthan (2) and Uttarakhand (1). As many as 290 cases of KP.2 have been registered with Maharashtra reporting the highest number at 148, according to the data. The other states and Union territories are Delhi (1), Goa (12), Gujarat (23), Haryana (3), Karnataka (4), Madhya Pradesh (1), Odisha (17), Rajasthan (21), Uttar Pradesh (8), Uttarakhand (16) and West Bengal (36). Singapore is seeing a new COVID-19 wave as the authorities recorded more than 25,900 cases from May 5 to 11 with KP.1 and KP.2 accounting for over two-thirds of cases in Singapore. Globally, the predominant COVID-19 variants are still JN.1 and its sub-lineages, including KP.1 and KP.2. KP.1 and KP.2 belong to a group of COVID-19 variants scientists have nicknamed 'FLiRT', after the technical names of their mutations. The strains in FLiRT are all descendants of the JN.1 variant, an offshoot of the Omicron variant. KP.2 was classified by the World Health Organization as a Variant Under Monitoring.

290 cases of COVID-19 variant KP.2, 34 cases of KP.1 detected in India: INSACOG data

<keyword id="19895045" type="General" weightage="20" keywordseo="Singapore" source="keywords">Singapore</keyword> is seeing a new <keyword id="21710881" type="General" weightage="20" keywordseo="Covid-19-wave" source="keywords">COVID-19 wave</keyword> as the authorities recorded more than 25,900 cases from May 5 to 11 even as <keyword id="19962428" type="General" weightage="20" keywordseo="Health-Minister" source="keywords">Health Minister</keyword> <keyword id="19895083" type="General" weightage="20" keywordseo="Ong-Ye-Kung" source="keywords">Ong Ye Kung</keyword> on Saturday advised the wearing of masks again. "We are at the beginning part of the wave where it is steadily rising," said Ong. "So, I would say the wave should peak in the next two to four weeks, which means between mid- and end of June," The Straits Times newspaper quoted the minister as saying. The Ministry of Health (MOH) said the estimated number of COVID-19 cases in the week of May 5 to 11 rose to 25,900 cases, compared with 13,700 cases in the previous week. The average daily COVID-19 hospitalisations rose to about 250 from 181 the week before. The average daily intensive care unit (ICU) cases remained low at three cases, compared with two cases in the previous week. The MOH said that to protect hospital bed capacity, public hospitals have been asked to reduce their non-urgent elective surgery cases and move suitable patients to transitional care facilities or back home through Mobile Inpatient Care@Home, an alternative inpatient care delivery model that offers clinically suitable patients the option of being hospitalised in their own homes instead of a hospital ward. Ong urged those who are at greatest risk of severe disease, including individuals aged 60 years and above, medically vulnerable individuals and residents of aged care facilities, to receive an additional dose of the COVID-19 vaccine if they have not done so in the last 12 months. Ong said that if the number of COVID-19 cases doubles one time, Singapore will have 500 patients in its healthcare system, which is what Singapore can handle. However, if the number of cases doubles a second time, there will be 1,000 patients, and "that will be a considerable burden on the hospital system", he pointed out. "One thousand beds is equivalent to one regional hospital," Ong said. "So, I think the healthcare system has to brace ourselves for what is to come." There are no plans for any form of social restrictions or any other mandatory kind of measures for now, as COVID-19 is treated as an endemic disease in Singapore, he said, adding that imposing additional measures would be a last resort. Ong said that with Singapore being a transport and communications hub, it will be one of the cities to get a wave of COVID-19 earlier than others. "So, COVID-19 is just something that we have to live with. Every year, we should expect one or two waves," he said. Globally, the predominant COVID-19 variants are still JN.1 and its sub-lineages, including KP.1 and KP.2. Currently, KP.1 and KP.2 account for over two-thirds of cases in Singapore. As of May 3, the World Health Organisation has classified KP.2 as a variant under monitoring. There are currently no indications, globally or locally, that KP.1 and KP.2 are more transmissible or cause more severe disease than other circulating variants, the MOH said. However, members of the public are urged to stay updated with vaccinations to protect themselves against current and emerging virus strains. The MOH said that to date, about 80 per cent of the local population have completed their initial or additional dose, but have not received a dose within the last year. The ministry added that since COVID-19 vaccination started in 2020 to 2021, the vaccines have consistently been proven to be safe and effective in protecting individuals from severe illness. Billions of doses have been administered globally, and safety monitoring internationally has shown that the vaccine is safe, it said. There have also been no long-term safety concerns with COVID-19 vaccination, and adverse effects from vaccines, including the mRNA vaccines, have all been observed to occur shortly after vaccination, the ministry added. SEE ALSO:<a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank">Motorola Edge 50 Fusion vs OnePlus Nord CE 4 – price, specs and features compared</a><a href="https://www.businessinsider.in/tech/mobile/webstories/iqoo-z9x-5g-with-120hz-display-6000mah-launched-starting-at-12999/slidelist/110176453.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/webstories/iqoo-z9x-5g-with-120hz-display-6000mah-launched-starting-at-12999/slidelist/110176453.cms" target="_blank">iQOO Z9x 5G with 120Hz display, 6000mAh launched starting at ₹12,999</a><a href="https://www.businessinsider.in/india/news/woman-loses-54-lakh-in-work-from-home-scam-heres-what-it-is-and-how-to-protect-yourself/articleshow/110166963.cms" target="_blank"></a> <a href="https://www.businessinsider.in/india/news/woman-loses-54-lakh-in-work-from-home-scam-heres-what-it-is-and-how-to-protect-yourself/articleshow/110166963.cms" target="_blank">Woman loses ₹54 lakh in work-from-home scam! Here's what it is and how to protect yourself</a>

Singapore seeing new COVID-19 wave, minister advises wearing of masks

The pharmaceutical giant <keyword id="19910149" type="General" weightage="20" keywordseo="AstraZeneca" source="keywords" meta.keywordsubtype="org" meta.entityname="AstraZeneca" meta.hostid="261" meta.entityid="AstraZeneca">AstraZeneca</keyword>'s <keyword id="20040659" type="General" weightage="20" keywordseo="COVID-19-vaccine" source="keywords">COVID-19 vaccine</keyword> is being withdrawn worldwide after the company acknowledged for the first time in court documents that it can cause a rare and dangerous side effect, according to a report in the British Newspaper 'The Telegraph'. AstraZeneca has announced that the <keyword id="19959412" type="General" weightage="20" keywordseo="vaccine" source="keywords">vaccine</keyword> was being removed from markets for commercial reasons. It further said that the vaccine was no longer being made or supplied, having been superseded by updated vaccines that fight new variants. The application to withdraw the vaccine was made on March 5 and came into effect on May 7. The vaccine can be no longer used in the European Union following the company's decision to withdraw its "marketing authorisation." Similar applications will be submitted in the UK and other nations in the coming months that have given a go-ahead to the vaccine, known as Vaxzevria. In recent months, Vaxzevria has come under scrutiny over a very rare side effect, which causes blood clots and low blood platelet counts. In court documents, AstraZeneca in the High Court in February admitted that the vaccine "can, in very rare cases, cause <keyword id="20218859" type="General" weightage="20" keywordseo="TTS" source="keywords">TTS</keyword>". TTS which stands for <keyword id="21475609" type="General" weightage="20" keywordseo="Thrombosis-with-Thrombocytopenia-Syndrome" source="keywords">Thrombosis with Thrombocytopenia Syndrome</keyword> has been associated with at least 81 deaths in the UK and hundreds of serious injuries. More than 50 alleged victims and grieving relatives have filed a lawsuit against AstraZeneca in a High Court case. AstraZeneca has insisted that the decision to withdraw the vaccine is not related to the case or admission that it can cause TTS and termed the timing a pure coincidence, according to The Telegraph report. "We are incredibly proud of the role Vaxzevria played in ending the global pandemic. According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over three billion doses were supplied globally. Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic," The Telegraph quoted AstraZeneca as saying. In a statement, the pharmaceutical giant said, "As multiple, variant Covid-19 vaccines have since been developed, there is a surplus of available updated vaccines", adding that it has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied, The Telegraph reported. It further announced its decision to initiate the withdrawal of the marketing authorisations for Vaxzevria within Europe. The company said, "We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the Covid-19 pandemic." Last week, AstraZeneca reiterated its commitment to patient safety while emphasising the vaccine's overall safety profile. An AstraZeneca spokesperson had stated, "Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority, and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines." This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its <keyword id="19896627" type="General" weightage="20" keywordseo="covid" source="keywords">Covid</keyword> vaccine Covishield and Vaxzevria "can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)." Despite these rare occurrences, the pharmaceutical company maintained that extensive clinical trial data and real-world evidence consistently support the vaccine's safety and efficacy. Regulatory agencies worldwide continue to assert that the benefits of vaccination outweigh the risks of such extremely rare side effects. SEE ALSO:<a href="https://www.businessinsider.in/stock-market/webstories/aadhar-housing-finance-ipo-price-band-to-risk-factors-all-you-need-to-know/slidelist/109919298.cms" target="_blank"></a> <a href="https://www.businessinsider.in/stock-market/webstories/aadhar-housing-finance-ipo-price-band-to-risk-factors-all-you-need-to-know/slidelist/109919298.cms" target="_blank">Aadhar Housing Finance IPO – Price band to risk factors, all you need to know</a><a href="https://www.businessinsider.in/business/auto/webstories/top-selling-cars-in-india-in-april-2024-tata-punch-continues-to-dominate/slidelist/109909744.cms" target="_blank"></a> <a href="https://www.businessinsider.in/business/auto/webstories/top-selling-cars-in-india-in-april-2024-tata-punch-continues-to-dominate/slidelist/109909744.cms" target="_blank">Top-selling cars in India in April 2024 – Tata Punch continues to dominate</a><a href="https://www.businessinsider.in/tech/news/worldwide-tablet-shipments-grow-in-q1-2024-after-two-years-of-decline/articleshow/109876390.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/news/worldwide-tablet-shipments-grow-in-q1-2024-after-two-years-of-decline/articleshow/109876390.cms" target="_blank">Worldwide tablet shipments grow in Q1 2024 after two years of decline</a>

AstraZeneca withdraws COVID-19 vaccine worldwide, cites commercial reasons

New <keyword id="1609796" type="General" weightage="100" keywordseo="omicron" source="Orion">Omicron</keyword> subvariants BQ.1 and BQ.1.1 have accounted for about 70 per cent of new Covid-19 cases in the US as the country's overall caseload has surpassed 100 million, according to the latest estimates by the <keyword id="116293" type="General" weightage="50" keywordseo="centers-for-disease-control-and-prevention" source="Orion">Centers for Disease Control and Prevention</keyword> (<keyword id="6379474" type="General" weightage="50" keywordseo="cdc" source="Orion">CDC</keyword>). BQ.1.1 was estimated to make up about 38.4 per cent of circulating variants in the week ending December 17, and BQ.1 was estimated to make up 30.7 per cent, according to CDC data. The two variants are descendants of Omicron's BA.5 subvariant and they have been growing especially fast since October, reports Xinhua news agency citing the data. At the beginning of October, each of the two new variants accounted for about 1 per cent of new infections. They replaced BA.5 to be dominant strains in mid-November. BA.5 only accounted for 10 per cent of new infections in the latest week. Another Omicron subvariant XBB is also on the rise, accounting for 7.2 per cent of new infections. Researchers found that the BQ and XBB subvariants are "barely susceptible to neutralization" by the vaccines, including the new Omicron boosters, according to a study published recently in the journal <keyword id="6452450" type="General" weightage="50" keywordseo="cell" source="Orion">Cell</keyword>. This could result in a surge of breakthrough infections and reinfections, though the vaccines have been shown to hold up against severe disease, according to the study. In its latest update on Wednesday, according to data from <keyword id="210763" type="General" weightage="50" keywordseo="johns-hopkins-university" source="Orion">Johns Hopkins University</keyword>. As of Wednesday, Johns Hopkins University said that country's overall caseload now stood at 100,003,814, while the death toll increased to 1,088,236. With the highest number of cases and deaths, the US remains the worst-hit country in the world. It accounts for more than 15 per cent of the global caseload and over 16 per cent of the overall fatalities. The country's Covid caseload reached 50 million on December 13, 2021, crossed 60 million on January 9, 2022, exceeded 70 million on January 21, topped 80 million on March 29, and surpassed 90 million on July 21. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/thelife/news/lucky-number-in-2023-based-on-date-of-birth-and-zodiac-sign/slidelist/96362537.cms">Lucky Number based on zodiac Sign in 2023</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/tawang-to-get-more-mobile-towers-for-better-connectivity-after-india-china-clash/articleshow/96390882.cms">Tawang to get more mobile towers for better connectivity after India-China clash</a>

You Searched For "omicron covid 19 cases" and got 5 results

Is AI dominance inevitable? A technology ethicist says no, actually

PTI

290 cases of COVID-19 variant KP.2, 34 cases of KP.1 detected in India: INSACOG data

PTI

Singapore seeing new COVID-19 wave, minister advises wearing of masks

PTI

AstraZeneca withdraws COVID-19 vaccine worldwide, cites commercial reasons

ANI

New Omicron subvariants account for nearly 70% new Covid cases in US

IANS

Popular Keywords

Buying Guides